Global Pouchitis Treatment Market, By Treatment (Antibiotics, Probiotics, Others), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2029.
Market Analysis and Insights
Pouchitis is an infrlammatory diseases of pouch. It develops in the lining of the pouch during surgery to treat ulcerative colitis or other type of colitis disease. Fecal incontinence, fever, diarrohea, abdominal pain, joint pain and cramps are the common symptoms. Therefore, pouchitis treatment is a medical procedure undergone to treat such symptoms and get rid of the disease itself.
- The pouchitis treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the pouchitis treatment market will grow at a CAGR of 11.50% during the forecast period of 2022 to 2029.
Pouchitis Treatment Market Dynamics
Surging incidence rate of inflammation in paients or inflammatory diseases is directly propelling the demand for effective medical treatment. Fatty liver, asthma, Atopic dermatitis, Crohn's disease and psoriasis are some common inflammatory diseases.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of the market is the rising healthcare expenditure which helps in improving its infrastructure. Growth and expansion of healthcare industry especially in the developing economies would invite the use and application of new and advanced medial technologies, equipment and drugs. This will directly increase the demand for pouchitis treatment.
Research and development activities
Growing number of strategic collaboration between public and private market players is inducing growth in the number of research and development activities on daily basis. These research and development proficiencies are being conducted in the area of novel drugs and medical technologies which will propel the demand for pouchitis treatment.
Furthermore, unhealthy lifestyle of individuals, rising initiatives by public and private organizations to spread awareness and increased consumption of tobbacco are the factors that will expand the market growth rate. Other factors such as increase in the demand for effective therapies and rising adoption rate for early diagnostic procedures will positively impact the market's growth rate.
Rise in the level of personal disposable income and growing awareness in the developing economies pertaining to the availability of treatment options will further create lucrative market growth opportunities. Rising medical tourism globally, growing availability of cost effective drugs and high potential of growth in the untapped market will create enough market growth opportunities.
However, high costs associated with research and development proficiencies will emerge as one of the biggest restraints for the market. Dearth of awareness and required infrastructural facilities in the underdeveloped and backward economies, stringent regulations imposed by the Food and Drug Administration (FDA) and unfavourable conditions arising due to COVID-19 outbreak will further derail the market growth rate. Slow rate of approval for drugs and inhibitors, side effects of the available treatment options and increasing cases of patent expiry will also challenge the market growth rate.
This pouchitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on pouchitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to the Centres for Disease Control and Prevention, in 2015, prevalence of ulcerative colitis is reported to be 37 to 246 cases per 100,000 individuals.
The pouchitis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Pouchitis Treatment Market
COVID-19 has led to denting the pouchitis treatment market growth rate. The consumer demand has subsequently reduced owing to the increased focus towards reducing non-essential expenses. Further, supply chain disruptions owing to restrictions and lockdown have hampered to effectivity of online and offline distribution channels. Also, low demand from food and beverages industry and halted manufacturing has worsened the siyuatiion for the market.
- In February 2019, the U.S. Food and Drug Administration (FDA) approved TREMFYA® One-Press, a single-dose, patient-controlled injector for adults, by Janssen Pharmaceutical Companies of Johnson & Johnson.
Global Pouchitis Treatment Market Scope
The pouchitis treatment market is segmented on the basis of treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
On the basis of treatment, the pouchitis treatment market is segmented into antibiotics, probiotics and others.
Route of administration
Route of administration segment of the pouchitis treatment market is segmented into oral and parenteral and others.
- Specialty Clinics
On the basis of end-users, the pouchitis treatment market is segmented into hospitals, specialty clinics and others.
- Hospital Pharmacy
- Retail Pharmacy
On the basis of distribution channel, the pouchitis treatment market has also been segmented into hospital pharmacy, retail pharmacy and others.
In October 2018, Amgen launched AMGEVITA, the first adalimumab biosimilar for the treatment of moderate to severe treatment of the disease. Takeda Pharmaceutical Company LimitedAstraZeneca, Pfizer, Inc., GlaxoSmithKline PLC, Boehringer Ingelheim GmbH and others are the involved in the development of potential drugs for the improvement of treatment of pouchitis treatment.
Pouchitis Treatment Market Regional Analysis/Insights
The pouchitis treatment market is analysed and market size insights and trends are provided by country, treatment, route of administration, end-users and distribution channel as referenced above.
The countries covered in the pouchitis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the pouchitis treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players, well-developed healthcare infrastructure in this region and increase in the incidence of psoriasis and favorable reimbursement policies. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increase in the awareness about psoriasis in developing countries and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Pouchitis Treatment Market Share Analysis
The pouchitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pouchitis treatment market.
Some of the major players operating in the pouchitis treatment market are AstraZeneca, Teva Pharmaceutical Industries Ltd. Sebela Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Strides Pharma Science Limited., Tolmar Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., LUPIN., Bausch Health., Sanofi, Synergy Pharmaceuticals, Atlantic Healthcare, Abbott, Takeda Pharmaceutical Company Limited, Ironwood Pharmaceuticals, Inc., Cipla Inc., Novartis AG and Glenmark Pharmaceuticals Ltd., among others.